Ustekinumab is indicated for the treatment of adult patients with moderate to severe active Crohn's disease (CD) who have had an inadequate response, loss of response, or intolerance to conventional therapy or tumor necrosis factor alpha (TNFα) antagonists (e.g., infliximab, adalimumab); it is also approved for the treatment of plaque psoriasis, including as a first-line agent for adult patients with moderate to severe plaque psoriasis according to the 2011 American Academy of Dermatology (AAD) guidelines; additionally, it is used in the treatment of psoriatic arthritis.